Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 14.97 2.25% 0.33
STML closed up 2.25 percent on Friday, May 24, 2019, on 68 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical STML trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Fell Below 20 DMA Bearish 2.25%
Bollinger Band Squeeze Range Contraction 2.25%
NR7 Range Contraction 2.25%
BB Squeeze Started Range Contraction 2.25%
20 DMA Support Bullish -1.06%
Crossed Above 20 DMA Bullish -0.86%
50 DMA Support Bullish 4.69%
20 DMA Resistance Bearish 2.89%
NR7 Range Contraction 2.89%

Older signals for STML ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Biopharmaceutical Cancer Biology Stem Cells Tumor Platform Technology Refractory Acute Myeloid Leukemia Carcinogenesis Cancer Stem Cell Cancer Stem Cells
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 20.55
52 Week Low 7.82
Average Volume 590,304
200-Day Moving Average 13.3422
50-Day Moving Average 14.1303
20-Day Moving Average 15.0718
10-Day Moving Average 14.6585
Average True Range 0.8009
ADX 15.32
+DI 19.8141
-DI 21.8636
Chandelier Exit (Long, 3 ATRs ) 13.9473
Chandelier Exit (Short, 3 ATRs ) 15.9527
Upper Bollinger Band 16.1709
Lower Bollinger Band 13.9727
Percent B (%b) 0.45
BandWidth 14.584854
MACD Line 0.185
MACD Signal Line 0.2816
MACD Histogram -0.0966
Fundamentals Value
Market Cap 351.12 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -6.06
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.20
Resistance 3 (R3) 16.07 15.54 15.99
Resistance 2 (R2) 15.54 15.23 15.60 15.92
Resistance 1 (R1) 15.26 15.04 15.40 15.38 15.86
Pivot Point 14.72 14.72 14.80 14.79 14.72
Support 1 (S1) 14.44 14.41 14.58 14.56 14.08
Support 2 (S2) 13.91 14.22 13.97 14.02
Support 3 (S3) 13.62 13.91 13.95
Support 4 (S4) 13.74